Login to Your Account



Clinic Roundup


Wednesday, October 9, 2013

• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, presented additional results from its pivotal Phase III study of Lymphoseek (technetium Tc 99m timlanocept) in patients with head and neck squamous cell carcionoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription